Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study.

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Clinical Oncology

Topics

Medicine

Cancer Oncology

Immunology

Internal Medicine

Radiology, Nuclear Medicine And Imaging

Show all topics

DOI

10.1200/jco.2024.42.16_suppl.2519